Company Overview of Tacere Therapeutics, Inc.
Tacere Therapeutics, Inc. develops therapeutics for the treatment of infectious diseases. The company’s therapeutic compound is TT-033i, an RNA interference drug for the treatment of Hepatitis C. The company was founded in 2006 and is based in San Jose, California. As of October 30, 2012, Tacere Therapeutics, Inc. operates as a subsidiary of Benitec Biopharma Limited.
5941 Optical Court
San Jose, CA 95138
Founded in 2006
Key Executives for Tacere Therapeutics, Inc.
Similar Private Companies By Industry
|1st Order Pharmaceuticals, Inc.||United States|
|21st Century Animal Health||United States|
|3 Buds' Organics LLC||United States|
|4P Therapeutics LLC||United States|
|60° Pharmaceuticals, LLC||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|NYC2012, Inc.||United States|
|The Advertising Council, Inc.||United States|
|Rush University||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact Tacere Therapeutics, Inc., please visit www.benitec.com/about/tacere-therapeutics. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.